BSH-IN-1 is primarily utilized in research settings, particularly in the study of boron neutron capture therapy (BNCT). It serves as an inhibitor targeting boronophenylalanine (BPA) uptake, which is critical for enhancing the selectivity and efficiency of BNCT in cancer treatment. By modulating the uptake of boron compounds in cancer cells, BSH-IN-1 helps improve the precision of neutron irradiation, minimizing damage to healthy tissues. Its application is significant in advancing therapeutic strategies for treating malignancies such as glioblastoma and other solid tumors. Researchers also explore its potential in combination therapies to optimize treatment outcomes.